# Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma

> **NCT00868608** · PHASE2 · COMPLETED · sponsor: **Pfizer** · enrollment: 81 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Inotuzumab Ozogamicin (CMC-544)

## Key facts

- **NCT ID:** NCT00868608
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07-30
- **Primary completion:** 2012-01-10
- **Final completion:** 2013-06-27
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2017-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00868608

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00868608, "Study Evaluating Inotuzumab Ozogamicin (CMC-544) In Indolent Non-Hodgkins Lymphoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00868608. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*